“Yale University has launched a multicenter clinical trial, sponsored by Stand Up to Cancer and Melanoma Research Alliance, that will apply the latest in personalized medicine technology to treat metastatic melanoma. The trial, for which Yale is a lead site, will enroll patients lacking a particular genetic mutation for whom immune therapy did not work or was not an option.
“Metastatic melanoma is a type of cancer that has spread from the skin to other parts of the body, most frequently the lungs, muscle, and liver. It is the most advanced and deadly type of melanoma, and notoriously difficult to treat.
” ‘Metastatic melanoma is one of those cancers for which we have distressingly few treatment options after immune therapy has failed,’ said Patricia M. LoRusso, associate director of Innovative Medicine at Yale Cancer Center and national co-principal investigator of the Melanoma Dream Team. ‘This partnership of cancer centers, research organizations, and industry offers the best chance we’ve had in long time to find solutions for melanoma patients. We think the personalized medicine approach is the way forward.’ “